Using immune cells to predict response to immunotherapy in advanced liver cancer
Assessment of Circulating Immune Cells as a Prognostic Factor in Patients With Advanced Hepatocellular Carcinoma Treated With Immunotherapy
This study is testing if certain immune cells can help predict how well patients with advanced liver cancer will respond to a new combination treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | Atezolizumab, Bevacizumab, immunotherapy |
| Locations | 1 site (Paris) |
| Trial ID | NCT05044676 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify immune cells as potential biomarkers for predicting responses to immunotherapy in patients with advanced hepatocellular carcinoma (HCC). Given the limited treatment options and poor outcomes associated with traditional therapies, the study focuses on patients receiving a combination of Atezolizumab and Bevacizumab. By analyzing immune responses and the presence of specific immune cells, the researchers hope to improve treatment strategies and outcomes for HCC patients. The study will include patients with measurable untreated lesions and a performance status of 0 or 1.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with advanced hepatocellular carcinoma who are eligible for systemic therapy with Atezolizumab and Bevacizumab.
Not a fit: Patients with HIV, autoimmune diseases, or those who have undergone liver transplantation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with advanced hepatocellular carcinoma.
How similar studies have performed: Other studies have shown promise in using immune markers to predict responses to immunotherapy, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Advanced hepatocellular carcinoma with an indication of systemic therapy by Atezolizumab-Bevacizumab * At least one measurable untreated lesion * ECOS performance status of 0 or 1 Exclusion Criteria: * HIV/ immunosuppressive treatment * Active of history of autoimmune disease or immune deficiency * Priori history of liver transplantation or systemic porto shunt * Pregnant of breastfeeding women
Where this trial is running
Paris
- Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière — Paris, France (Recruiting)
Study contacts
- Principal investigator: Manon ALLAIRE, MD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Manon ALLAIRE, MD
- Email: manon.allaire@aphp.fr
- Phone: 01 42 16 10 34
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.